Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Lonidamine






●Italiano
 ●Русский
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Lonidamine
Clinical data
ATC code
Identifiers

  • 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid

CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.051.356 Edit this at Wikidata
Chemical and physical data
FormulaC15H10Cl2N2O2
Molar mass321.16 g·mol−1
3D model (JSmol)

  • C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O

  • InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21) ☒N

  • Key:WDRYRZXSPDWGEB-UHFFFAOYSA-N ☒N

 ☒NcheckY (what is this?)  (verify)

Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.[1]

Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. This is due to its proven ability to inhibit energy metabolism in cancer cells, and to enhance the activity of anticancer agents.[1]

Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide.[2] An in-vitro study showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.[2]

A derivative of lonidamine, gamendazole, is in testing as a possible male contraceptive pill.[3]

References

[edit]
  1. ^ a b Pelicano H, Martin DS, Xu RH, Huang P (August 2006). "Glycolysis inhibition for anticancer treatment". Oncogene. 25 (34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID 16892078.
  • ^ a b Prabhakara S, Kalia VK (August 2008). "Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine" (PDF). Indian J. Med. Res. 128 (2): 140–8. PMID 19001677.
  • ^ Tash, Joseph (July 2008). "A Novel Potent Indazole Carboxylic Acid Derivative Blocks Spermatogenesis and Is Contraceptive in Rats after a Single Oral Dose". Biology of Reproduction. 78 (6): 1127–1138. doi:10.1095/biolreprod.106.057810. PMID 18218612.


    • Stub icon

    This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Lonidamine&oldid=1214151039"
    Categories: 
    ●Antineoplastic drugs
     ●Indazoles
     ●Antineoplastic and immunomodulating drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles with changed ChemSpider identifier
     ●ECHA InfoCard ID from Wikidata
     ●Articles with changed InChI identifier
     ●Chemical pages without DrugBank identifier
     ●Drugs with no legal status
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 17 March 2024, at 06:52 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki